Table 1.

Patient baseline demographics and clinical characteristics

	PF‐03446962 dose
	4.5 mg/kgn = 4		7 mg/kgn = 13		10 mg/kgn = 19
	Male	Female	Male	Female	Male	Female	Total N = 36
No. of patients	3	1	8	5	14	5	36
Age, years
Median	64.0	49.0	56.0	53.0	60.0	56.0	56.5
Range	51–72	–	41–79	37–62	29–75	55–66	29–79
Race, n
Japanese	2	1	3	2	9	2	19
Korean	1	0	5	3	5	3	17
ECOG PS, n (%)
0	3 (75.0)		7 (53.8)		13 (68.4)		23 (63.9)
1	1 (25.0)		6 (46.2)		6 (31.6)		13 (36.1)
Prior surgeries, n (%)
No	1 (25.0)		2 (15.4)		3 (15.8)		6 (16.7)
Yes	3 (75.0)		11 (84.6)		16 (84.2)		30 (83.3)
Prior radiation therapy, n (%)
No	3 (75.0)		9 (69.2)		17 (89.5)		29 (80.6)
Yes	1 (25.0)		4 (30.8)		2 (10.5)		7 (19.4)
Prior non‐VEGFR‐targeted systemic therapies, n (%)
No	0		1 (7.7)		2 (10.5)		3 (8.3)
Yes	4 (100)		12 (92.3)		17 (89.5)		33 (91.7)
Prior VEGFR‐targeted systemic therapies, n (%)
No	0		1 (7.7)		6 (31.6)		7 (19.4)
Yes	4 (100)		12 (92.3)		13 (68.4)		29 (80.6)

ECOG PS, Eastern Cooperative Oncology Group performance score; VEGFR, vascular endothelial growth factor receptor.